Phillip D Harvey
Overview
Explore the profile of Phillip D Harvey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yohn S, Harvey P, Brannan S, Horan W
Front Psychiatry
. 2024 Nov;
15:1421554.
PMID: 39483736
Cognitive impairment is a core symptom of schizophrenia and a major determinant of poor long-term functional outcomes. Despite considerable efforts, we do not yet have any approved pharmacological treatments for...
2.
Daniel D, Cohen A, Velligan D, Harvey P, Alphs L, Davidson M, et al.
Schizophr Bull Open
. 2024 Aug;
4(1):sgad001.
PMID: 39145343
In contrast to the validated scales for face-to-face assessment of negative symptoms, no widely accepted tools currently exist for remote monitoring of negative symptoms. Remote assessment of negative symptoms can...
3.
Lieberman A, Parrish E, Depp C, Harvey P, Pinkham A, Joiner T
Arch Suicide Res
. 2023 Apr;
28(2):554-568.
PMID: 37013824
Introduction: Individuals with schizophrenia are at increased risk for suicide, and the Demoralization Hypothesis states that non-delusional awareness of one's social, cognitive, or occupational deterioration elicits depression and hopelessness. Both...
4.
Rabinowitz J, Staner C, Saoud J, Weiser M, Kuchibhatla R, Davidson M, et al.
Schizophr Res
. 2023 Mar;
255:9-13.
PMID: 36933291
Roluperidone has antagonist properties for 5-HT, sigma, α- and α-adrenergic receptors, but no dopaminergic binding affinities. In 2 randomized controlled trials (RCT), treatment improved negative symptoms of schizophrenia and social...
5.
Strassnig M, Newcomer J, Harvey P
Schizophr Res
. 2012 Sep;
141(2-3):284-5.
PMID: 22959487
No abstract available.
6.
Keefe R, Vinogradov S, Medalia A, Buckley P, Caroff S, DSouza D, et al.
J Clin Psychiatry
. 2012 Jun;
73(7):1016-22.
PMID: 22687548
Background: The true benefit of pharmacologic intervention to improve cognition in schizophrenia may not be evident without regular cognitive enrichment. Clinical trials assessing the neurocognitive effects of new medications may...
7.
Mausbach B, Harvey P, Goldman S, Jeste D, Patterson T
Schizophr Bull
. 2007 Mar;
33(6):1364-72.
PMID: 17341468
We developed and tested the validity of a brief scale to assess everyday functioning in persons with serious mental illness. A sample of 434 adults with schizophrenia or schizoaffective disorder...
8.
Koren D, Seidman L, Goldsmith M, Harvey P
Schizophr Bull
. 2006 Jan;
32(2):310-26.
PMID: 16397202
While the role of impaired cognition in accounting for functional outcome in schizophrenia is generally established by now, the overlap is far from complete. Moreover, little is known about the...
9.
Mitropoulou V, Harvey P, Zegarelli G, New A, Silverman J, Siever L
Am J Psychiatry
. 2005 Oct;
162(10):1896-903.
PMID: 16199836
Background: Cognitive deficits consistently have been reported in schizophrenia patients and in patients with schizotypal personality disorder. For this study, the authors wanted to identify which of the domains of...
10.
DeLisi L, Maurizio A, Svetina C, Ardekani B, Szulc K, Nierenberg J, et al.
Am J Med Genet B Neuropsychiatr Genet
. 2005 Feb;
135B(1):15-23.
PMID: 15729733
Males with an extra-X chromosome (Klinefelter's syndrome) frequently, although not always, have an increased prevalence of psychiatric disturbances that range from attention deficit disorder in childhood to schizophrenia or severe...